Clinical Trials Logo

Clinical Trial Details — Status: Suspended

Administrative data

NCT number NCT04697290
Other study ID # HXYT-012
Secondary ID
Status Suspended
Phase Early Phase 1
First received
Last updated
Start date March 10, 2022
Est. completion date June 10, 2023

Study information

Verified date January 2022
Source Beijing Tsinghua Chang Gung Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a single center, single arm, open-label, phase I study to evaluate the safety and efficacy of CD19/CD20 Dual-CAR-T cells in patients with refractory or relapsed B-NHL.


Description:

This Phase I study is designed as a pilot trial evaluating the safety and efficacy of CD19/CD20 Dual-CAR-T cell therapy in subjects with refractory and relapsed B-NHL. Subjects will receive cytoreductive chemotherapy with cyclophosphamide and fludarabine on days -5, -4 and -3 followed by infusion of CD19/CD20 Dual-CAR-T cells. Safety and efficacy of CD19/CD20 Dual-CAR-T cells therapy will be monitored. The purpose of current study is to determine the clinical efficacy and safety of CD19/CD20 Dual-CAR-T cells therapy in patients with refractory and relapsed B-NHL.


Recruitment information / eligibility

Status Suspended
Enrollment 12
Est. completion date June 10, 2023
Est. primary completion date March 10, 2023
Accepts healthy volunteers No
Gender All
Age group 1 Year to 80 Years
Eligibility Inclusion Criteria: 1. Age =18 years 2. NHL confirmed by cytology or histology, including diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, etc. 3. Relapse or refractory after at least second-line treatment; 4. With evaluable target lesions.Measurable target lesions: lymph nodes>1.5x1.0cm, extranodal lesions>1.0x1.0cm; 5. Double positive expression of CD19 / CD20 in B cells; 6. ECOG score 0-2 points; 7. Good organ function: Blood routine: absolute neutrophil count (ANC) =1.0×109/L; hemoglobin (Hb) =80 g/L; platelet count (PLT) =50×109/L; Blood biochemistry: total bilirubin=3×upper limit of normal (ULN), aspartate aminotransferase (AST) and alanine aminotransferase (ALT)=3×upper limit of normal (ULN); Pulmonary function: =CTCAE Grade 1 dyspnea and SaO2=92% in indoor air environment; Heart function: Left ventricular ejection fraction (LVEF) =50%. 8. Women of childbearing age (15-49 years old) must receive a pregnancy test within 7 days prior to initiation of treatment and the results are negative; male and female patients with fertility must use an effective contraceptive to ensure 3 months after discontinuation of treatment during the study period not pregnant inside; 9. Patients who voluntarily sign informed consent and are willing to comply with treatment plans. Exclusion Criteria: 1. Active infections that are difficult to control; 2. Active hepatitis B, active hepatitis C, human immunodeficiency virus (HIV) antibody positive, and Treponema pallidum antibody test positive; 3. The tumor invades the central nervous system or primary CNS lymphoma; 4. Anti-GVHD (acute or chronic) treatment is being performed within 4 weeks before apheresis and cell infusion; 5. Have undergone the following treatments: - Those who have received chemotherapy or radiotherapy 5 days before apheresis; - Those who have used drugs that stimulate the production of bone marrow hematopoietic cells within 5 days before apheresis; - Received donor lymphocyte infusion (DLI) within 6 weeks before cell infusion; - Have received autologous hematopoietic stem cell transplantation (HSCT) 3 months before apheresis, or received allogeneic hematopoietic stem cell transplantation (allo-HSCT) within 12 months; - Have used any gene therapy products before; 6. History of epilepsy or other central nervous system diseases; or clinically diagnosed as having severe thyroid dysfunction; or active autoimmune diseases; 7. History of other malignant tumors that have not been remission for at least 3 years ; 8. Any of the following cardiovascular diseases occurred within 6 months of the screening period, including NYHA heart function grade III or IV heart failure, cardiovascular angioplasty or stent, myocardial infarction, unstable angina, or other clinical symptoms Significant heart disease; 9. Pregnant or lactating women; 10. The investigator believes that there are other factors that are not suitable for selection or that affect subjects' participation or completion of the study.

Study Design


Intervention

Biological:
CD19/CD20 Dual-CAR-T cells
CD19/CD20 Dual-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest at least for 2 days before infusion. CD19/CD20 Dual-CAR-T cells will be intravenously infused with a escalated dose of 2E6?6E6?1E7?3E7 cells/kg.

Locations

Country Name City State
China Beijing Tsinghua Changgung Hospital Beijing Beijing

Sponsors (2)

Lead Sponsor Collaborator
Beijing Tsinghua Chang Gung Hospital China Immunotech Pharmaceuticals Co.Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other Persistence of CAR-T cells in vivo 6 months
Primary Percentage of adverse events Percentage of participants with adverse events. 6months
Primary Objective remission rate(ORR) The percentage of participants who achieved complete remission (CR) and partial remission over all participants. 6 months
Secondary Relapse-Free Survival(RFS ) 6 months
Secondary Overall-Survival(OS) 6 months
See also
  Status Clinical Trial Phase
Completed NCT00588094 - Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL Phase 2
Not yet recruiting NCT05091541 - A Phase 1/2 Study of CT120 in Patient With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma Phase 1/Phase 2
Recruiting NCT03639181 - Clinical Trial in Chinese Patients of B-cell Non-Hodgkin's Lymphoma(GB226) Phase 2
Recruiting NCT06104553 - A Trial of SHR-A1912 Combined With Other Therapies in B-cell Non-Hodgkin 's Lymphoma Phase 1/Phase 2
Terminated NCT01352312 - Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma Phase 1
Not yet recruiting NCT05771883 - A Clinical Study of Injectable IMM0306 in Combination With Lenalidomide Phase 1/Phase 2
Not yet recruiting NCT06314828 - A Tolerability, Safety and Efficacy Study of RJMty19 in Subjects With Relapsed or Refractory B-NHL Phase 1
Enrolling by invitation NCT05332054 - Long-Term Follow-up Study
Completed NCT02564744 - Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory DLBCL and Other Forms of NHL Phase 2
Recruiting NCT05453669 - Clinical Study of the Efficacy of CD19-CAR-DNT Cells in the Treatment of Relapsed/Refractory B-cell NHL Phase 1
Recruiting NCT05190068 - HMPL-760 in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma Phase 1
Suspended NCT04746131 - Safety and Pharmacokinetic Study of IMM0306 in Patients With Refractory or Relapsed CD20-positive B-cell Non-Hodgkin's Lymphoma (B-NHL) Phase 1
Active, not recruiting NCT00927797 - Interventional Study on Pentostatin, Cyclophosphamide and Rituximab in Indolent B-Cell Non-Hodgkin-Lymphoma (B-NHL) Phase 2
Recruiting NCT05436223 - Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma Phase 2
Completed NCT00457782 - A Phase I Safety, PK and PD Study of KW-2478 in Patients With Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's Lymphoma Phase 1
Not yet recruiting NCT03105596 - Chidamide Plus DICE Regimen for Patients With Relapse or Refractory B-cell Non-Hodgkin's Lymphoma (NHL) Phase 2